FERAL

Functional characterization of a novel rheumatoid arthritis susceptibility locus on chromosome 6q

Coordinatore	THE UNIVERSITY OF MANCHESTER    more  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: +44 (0)161 275 7114 Fax: +44 (0)161 275 4037
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	0 €
EC contributo	171˙867 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IEF-2008
Funding Scheme	MC-IEF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-06-01   -   2011-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE UNIVERSITY OF MANCHESTER  Organization address address: OXFORD ROAD city: MANCHESTER postcode: M13 9PL contact info Titolo: Ms. Nome: Liz Cognome: Fay Email: send email Telefono: +44 (0)161 275 7114 Fax: +44 (0)161 275 4037	UK (MANCHESTER)	coordinator	171˙867.62

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Rheumatoid arthritis (RA) is the commonest inflammatory disease of synovial joints. Approximately 50% of genetic susceptibility to RA is accounted for by the HLA-DRB1 gene together with the PTPN22 gene. A whole genome association (WGA) scan recently carried out by the Wellcome Trust Case Control Consortium (WTCCC) and subsequent validation studies have confirmed that an additional susceptibility locus maps to an inter-genic region of 6q23, near the TNFAIP3 gene. This is a strong candidate RA susceptibility gene as it is induced by TNF, a key inflammatory cytokine in RA. The aim of the project is to characterise the aetiological variant within this region and determine its role in RA susceptibility. The region is being re-sequenced in 80 individuals comprising both cases and controls to include representation of all 3 genotypes. Fine mapping studies will then be undertaken in the original samples included in the WTCCC study to identify the most strongly associated variants in the region. That data should be available by the start of the proposed Fellowship. I will test the most associated variants in an independent validation cohort of 5000 RA samples and 3800 healthy controls from the UK to confirm the most associated variant(s) and characterise the haplotype structure and linkage disequilibrium present in the region. Subsequently, bioinformatic resources will be used to investigate whether the associated variants mapping are associated with expression levels of genes in the region (particularly TNFAIP3) or are predicted to bind transcription factors. Functional studies will then be undertaken to clarify the role of these variants in RA ethiopathogenesis using techniques including luciferase reporter gene assays, electromobility shift assays, expression studies and analysis of protein levels. Experiments will be performed using relevant cell lines and tissues under both basal and TNF-stimulated conditions.'